AREV Life Sciences (AREV) is a fully integrated, early stage life science discovery enterprise dedicated to delivering solutions to public healthcare metrics through innovations and successful collaborations in the life science industry. Our strategy is dedicated to generating revenue by way of novel therapeutic approaches to human nutrition and malnutrition, pandemic diseases, and neglected chronic comorbidities.
We are invested in commercial innovations in phytomedicinal discoveries of small molecule antivirals and have a significant footprint in human nutrition including the development of a Ready-to-Use Therapeutic Food (RUTF) for Severe Acute Malnutrition (SAM) and an Enteral Formula targeting the long term effects of COVID-19. Through our Scientific Advisory Board (SAB) and strategic collaborations with Voynich Biosciences, we are connected to the Linus Pauling Institute at Oregon State University (OSU) and with the Institute of Human Virology. AREV is working with scientists at Voynich to serve as preclinical discovery partners for our REV inhibitor. Our SAB is reflective of industry leaders and academic collaborations.
AREV is dedicated to designing and delivering innovation in nutritional therapeutics and rational drug design, driven by molecular epidemiology. AREV’s business model is driven by leveraging its core competency of extraction to produce ingredients and compounds for its pipeline of products.
We are a small publicly traded life science enterprise invested in commercial innovations in phytomedical discoveries of small molecule antivirals and have a significant footprint in human nutrition.